Featured Stories

Flow Cytometry Enhances Syngeneic Mouse Models in Oncology Drug Discovery

02/06/2015

Immunocompetent syngeneic mouse tumor models serve as a surrogate for human patients and allow us to study how cancer therapies perform in conjunction with a functional immune system. Flow cytometry enables validation of a functional immune system and the ability to determine various cell populations. Evaluation of these cell populations then makes it possible to characterize an immune response elicited from novel therapeutics.

Charles River Germany and Italy Receive AAALAC Accreditation

02/02/2015

Charles River is proud to announce that its research model breeding and services facilities in Germany and Italy have both recently received full accreditation of their animal care and use programs from AAALAC International. Only a handful of commercial breeders in Europe have received this prestigious accreditation.

Introducing In Vivo Bone Microstructure Assessments in Large Animals with XtremeCT

01/29/2015

We have recently added the XtremeCT II to our musculoskeletal imaging platform. HR-pQCT provides a unique in vivo assessment of bone microarchitecture in large animals. Combined with traditional densitometry and imaging technologies, XtremeCT II represents a major translational imaging tool for drug development for musculoskeletal disorders.

Your Top Resources from Our Industry-Leading Ocular Research Scientists

01/21/2015

Over the past year, Charles River ocular experts collaborated with clients to complete an impressive 40 discovery and toxicology studies. As industry leaders, our scientists are committed to sharing this experience and keeping you informed on the latest trends and innovations in their field. 

Whole-Body Composition Assessment in Rodents

01/19/2015

In the treatment of clinical obesity, preclinical outcomes of adiposity remain critical to advancing the right drug candidate. However, there is much more to it than the scale.

Displaying results 1-10 (of 146)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|